Chief Executive Officer and Chief Investment Officer, ImpactAssets, joining the Summit from the San Francisco Bay Area

Margret's 25-year career includes executive leadership, investment and operating roles for large and small companies including Barclays Global Investors/Blackrock and Charles Schwab. Her experience spans investment management, product management, strategy and planning, reengineering, turnarounds and business building. Margret’s investment expertise spans direct private equity and venture capital, international equities, currency hedging, commercial real estate, energy, natural resources, ESG/values-aligned strategies and impact investing.

She founded Intentional Capital, a boutique private equity firm serving custom direct investments to a select group of family offices, many of whom have fully developed impact investing strategies. Margret also serves on the boards and investment committees of three family offices.

Margret graduated from Stanford Graduate School of Business and holds a degree in Economics from University of California Santa Barbara. Margret lives in San Francisco, CA with her husband and children.

President, Catalytic Impact Foundation (CIF), joining the Summit from Boston, Massachusetts

As President of the CIF, Rachel has extensive experience and expertise analyzing, evaluating, and investing in early- and mid-stage companies in the life sciences and healthcare industry.

Since 2016, she has reviewed hundreds of such companies and served as a team leader, overseeing and managing the research, analysis, and investment processes, to select companies for presentation and/or investment, beginning at Cavendish Global and then at CIF. She is a lead member of the investment team that invested in the CIF portfolio of innovative healthcare companies.

Previously, she served as co-founder and Editor-in-Chief of Asthma Magazine, a patient education publication for asthma and allergy. The magazine was used by the NHLBI to educate participants in its nationwide children’s asthma (CAMP) study; by Merck to launch its first-in-class asthma drug, Singulair; and by the American Lung Association, the American Academy of Asthma, Allergy and Immunology, the National Association of School Nurses, health maintenance organizations, disease management companies, and private practitioners throughout the country, to educate their patients about the condition. Subsequently, she guided the company through its acquisition by Elsevier Health Sciences, a leading publisher of medical journals, where she continued as Editor-in-Chief for five years.

She is a graduate of St. Lawrence University, a trustee and treasurer of the Ross Conservation Trust. She is married with four children and lives near Boston, MA.

Richard Hanbury, Chief Executive Officer, Sana Health, who joined the March Summit from Colorado

Richard Hanbury is the inventor of Sana, a neuromodulation platform for pain relief and deep relaxation, which he developed to eradicate his own life-threatening pain problem following a spinal-chord injury from a jeep crash near Sana, Yemen, in 1992. It is now his life’s mission to develop Sana to help others.

Sana is an at-home treatment for pain and mental health. Sana uses audio-visual neuromodulation to guide the brain into a deeply relaxed state, reducing anxiety and increasing neuroplasticity. Because of this Sana is the first device that is able to treat all the major compounding co-morbidities of chronic pain – pain, anxiety, depression, and sleep issues.

Sana is 90% complete on a pivotal FDA study - 120 person RCT at Duke University, and a 120 person RCT is also underway at Mount Sinai, for neuropathic pain.

Sana is seeking to carry out pivotal trials in anxiety, depression, MS pain, Cerebral Palsy, CRPS, CPS and PTSD.

Founder-developed to solve his own underlying nerve damage pain following a jeep crash in Yemen, the device is now poised to solve a large unmet need in the treatment of fibromyalgia, with multiple other pain and mental health indications to follow.

Learn more about Sana Health and meet Richard by logging in to Cavendish IQ..

Steve Stephansen, Chief Executive Officer, Lifewave Biomedical, who joined the Summit from the San Francisco Bay Area

Heart failure (or congestive heart failure) has been the disease of highest incidence and prevalence in the U.S. as well as the EU, Japan, Southeast Asia, and MENA (prior to COVID19). Heart failure has the highest hospitalization and re-hospitalization rates, highest cost to the healthcare system and highest mortality. Heart failure incidence continues to rapidly grow and while new therapies and interventions are being developed, it remains a challenging disease. Healthcare systems are seeking care improvements that enable better care in home and remote clinics.

LifeWave Biomedical is developing the CardioConnect™ system that will be the first cost effective non-invasive physiologic sensor that delivers a single clinically actionable parameter that can enable guided-care in home environments. The CardioConnect system is being designed to reduce hospitalization, improve quality-of-life, and significantly lower cost to health care systems in treating the disease.

Steve Stephansen is the CEO of LifeWave Biomedical. He holds 40 years of engineering, marketing, sales, and CEO experience in information technology businesses in both Fortune 500 and startup businesses. He is experienced in the global commercialization of innovative technology products, including semiconductor solutions for high speed computing and signal processing, Internet video capture systems, displays, and business connectivity software.

He has previous CEO experience at two technology startups, at WebV2, Inc. and Agoura Technologies, Inc. Previous to his CEO experience, he held the position of VP of Marketing & Sales at Information Storage Devices where he grew annual sales from $0 to $55M sales in four years, leading to successful initial and secondary public offerings.

He is a graduate of the Stanford Graduate School of Business, Rensselaer Polytechnic Institute, and Lehigh University.

Learn more about Lifewave BIomedical and meet Steve by logging in to Cavendish IQ.